Recently, employing radioligand displacement and functional coupling studies, we demonstrated that SB269,2,3, ]nemonapride dissociation, the present data suggest that SB269,652 behaves as a bitopic antagonist at unoccupied dopamine D 3 receptor, binding simultaneously to both orthosteric and allosteric sites, and as a pure negative allosteric modulator when receptors are occupied and it can solely bind to the allosteric site.
Introduction
Dopamine D 3 receptors are members of the dopamine D 2 -like family of G protein-coupled receptors (GPCRs) that signal via the Gα i class of GTP-binding proteins to inhibit adenylyl cyclase and activate diverse kinase signaling cascades (Sokoloff and Le Foll, 2017) . They are critically involved in a number of physiological processes such as the control of cognition, mood and motor behaviour (Beaulieu and Gainetdinov, 2011) . Accordingly, dopamine D 3 receptors may be a target for the treatment of neuropsychiatric disorders and, due to their enrichment in mesolimbic dopaminergic projection areas, they are of particular interest for the potential control of schizophrenia (Gross and Drescher, 2012; Millan et al., 2016) and drug addiction (Heidbreder and Newman, 2010; Joyce and Millan, 2005) .
Conventionally, and by analogy to dopamine D 2 receptors, the design of dopamine D 3 receptor ligands has focused on the orthosteric binding site (Pich and Collo, 2015) . However, in recent years, allosteric modulation of GPCR activity has attracted interest as an alternative route towards the development of selective and well-tolerated drugs for use either alone or together with other classes of agent. An attractive feature of positive and negative allosteric modulators is their concentration-response relationship, which plateaus, and permits the development of treatments with a broad therapeutic dose-range avoiding the risk of excessive activation or blockade of receptor-signaling: this underpins the interest in their clinical application either alone or as adjunctive treatments (Smith and Milligan, 2010; Hudson et al., 2013; Christopoulos, 2014) .H] spiperone were employed at 10-fold higher concentrations, SB269,652, even at very high concentrations, could only sub-maximally inhibit their specific binding at dopamine D 3 receptor. Similarly, SB269,652 potently blocked dopamine D 3 receptor-mediated activation of Gα i3 , however, when concentrations of dopamine were increased 10-folds, from 1 μM to 10 μM, SB269,652 inhibited dopamine-induced stimulation of Gα i3 only submaximally, indicating, once more, that SB269,652 behaved also as a negative allosteric modulator. Furthermore, the binding kinetics of [ 3 H]nemonapride and [ 3 H]spiperone at dopamine D 2 and dopamine D 3 receptors were clearly modified in the presence of SB269,652 compared with the two orthosteric antagonists, haloperidol and sulpiride. Taken together, these results strongly suggest that SB269,652 behaves as a negative allosteric modulator at dopamine D 2 and dopamine D 3 receptors -the first to be identified. The allosteric nature of this compound was subsequently confirmed by Lane et al. (2014) , Shonberg et al. (2015) , Mistry et al. (2015) for dopamine D 2 receptor and by Kumar et al. (2017) , for dopamine D 3 receptor, and now SB269,652 has become a leading compound in the synthesis of new allosteric drugs (Rossi et al., 2017) .
In view of this interest in allosteric modulators of dopaminergic receptors and more specifically, SB269,652, in the present work, this compound was radiolabelled in order to characterize its putatively allosteric actions at recombinant human dopamine D 3 receptor.
Materials and methods

Radiolabelled compounds
SB269,652
is a N-[(1r,4r)−4-[2-(7-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]−1H-indole-2-carboxamide. It has two diastereoisomers due to the presence of a cyclohexane moiety in its structure; the trans diastereoisomer was used in this work and was radiolabelled with tritium to a specific activity of 26 Ci/mmol. SB269,652 was synthesized by G. Lavielle (Servier, Paris, France The human dopamine D 3 receptor was used to make the dopamine D 3 D110A and the human dopamine D 3 -trunk receptor mutants. In the D 3 D110A construct, aspartate 110 in transmembrane region III was replaced by alanine. The dopamine D 3 -trunk receptor fragment was made by inserting a STOP codon into the dopamine D 3 receptor after amino acid isoleucine 290 and by removing the C-terminal part of the intracellular loop 3 and transmembrane regions VI and VII. The dopamine D 2 -trunk receptor fragment was generated as described in Scarselli et al. (2000) . The plasmids were transiently transfected in COS-7 cells by the DEAE-dextran chloroquine method. by Pierre Sokoloff (Sokoloff et al., 1992) . CHO-D 2L and CHO-D 1 cells were generated by transfecting the human dopamine D 2L or human dopamine D 1 receptors, respectively, in wild type CHO cells . CHO-hM 4 (human muscarinic M 4 receptor) cells were prepared as described previously in Maggio et al. (1995) . COS-7 cells were used for transient transfections. Briefly, cells were seeded at a density of 5 × 10 5 per 100-mm dish and 24 h later incubated with the DEAE-dextran chloroquine transfection reagent and with the respective plasmids as indicated for each experiment (Picchietti et al., 2009 ). The total amount of DNA used for each transfection was 4 μg (2 μg for each plasmid in co-transfection, unless otherwise specified.
2.4. Evaluation of the affinities of SB269,652 at human dopamine D 3 receptor, human dopamine D 2L receptor, and human dopamine D 2S receptor and at other classes of binding site SB269,652 affinities at various classes of dopaminergic receptors and other sites were determined using conventional procedures. All protocols used for determination of affinities of SB269,652 at the multiple classes of cloned receptors have been documented previously (Millan et al., 2008) . The cell lines and radioligands used for determination of affinities are summarized in Table 4 .
Membrane preparation and binding assays
Confluent plates were washed twice with cold 0.9% NaCl solution and lysed in ice-cold hypotonic buffer (1 mM Na-HEPES and 2 mM EDTA). After 20 min in ice, the cells were scraped off the plate and centrifuged at 35,000g for 20 min. The lysed cell pellet was homogenized with Polytron homogenizer in the binding assay buffer (50 mM TRIS-HCl pH 7.4, 155 mM NaCl and 0.01 mg/ml bovine serum albumin (Di Cara et al., 2011) . The synaptosomal pellet was homogenized with a Polytron homogenizer in the binding assay buffer, centrifuged and washed twice at 35,000g for 20 min. Membrane suspensions were used for binding studies.
Adenylyl cyclase (AC) assays
Twenty-four h after transfection, cells were transferred into 24-well plates and cultured for additional 24 h before running the adenylyl cyclase assays. In brief, the cells were incubated in fresh media for 2 h (0.25 ml/well) in the presence of 5 μCi/ml [ 3 H]adenine. The media was then replaced with 0.5 ml/well of Dulbecco's modified Eagle's medium containing 20 mM HEPES, pH 7.4, 0.1 mg bovine serum albumin, and the phosphodiesterase inhibitors, 1-methyl-3-isobutylxanthine (0.5 mM) and RO-20-1724 (0.5 mM) .
AC activity was stimulated by addition of 10 μM forskolin in the presence or absence of quinpirole. The antagonist SB269,652 or SB277,011A were added 20 min before the agonists.
After 10 min incubation at 30°C, the medium was removed and the reaction terminated with perchloric acid containing 0.1 mM unlabelled cAMP. The acid was then neutralized with KOH. The amount of [ 3 H] cAMP produced was determined by a two-step column separation procedure, as described previously in Maggio et al. (2003) . 
where L is the concentration of the radioligand. Statistics were run with iterative, non-linear least-squares regression analysis using OriginPro 7.5 software (OriginLab Corporation, Northampton, MA, USA). The goodness-of-fit of one or two sites models in equilibrium and kinetics binding experiments was compared using F-tests with significance set at P < 0.05. of 0.03 ± 0.002 (Table 3 and Fig. 2A ). Conversely, dissociation kinetics performed by dilution and addition of an excess of haloperidol or dopamine were best fitted by a two-phases exponential decay model (F 2,27 = 14.06 → P < 0.0001 and F 2,27 = 33.43 → P < 0.0001, respectively) ( (Table 3 ). In the presence of dopamine, fast dissociation of [ 3 H]SB269,652 accounts for 41% of the bound receptors, while with haloperidol this fraction dropped to 20% (Table 3) . Interestingly, dissociation kinetics performed in the presence of an excess of cold ligands resulted in association kinetics that were best fitted by a two-phase exponential growth function (Fig. 2D ). The two apparent association rate constants in the presence of 1.6 nM [
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3 H]SB269,652 were: K obb 1 = 0.553 ± 0.407 and K obb 2 = 0.037 ± 0.007 min −1 (Table 3) . Notably, the fast association rate constant accounted for 24.16% of the saturated receptors. ,652 in saturation experiments ranged from 0.05 to 5.5 nM (from 2860 to 314,600 dpm for sample), while its concentration in competition experiments was 1.6 nM (91,520 dpm per sample). In the saturation experiment, at 5.5 nM concentration of [ 3 H]SB269,652, the total binding was 5419 dpm while nonspecific binding was 1244 dpm, and the amount of proteins added in each sample was 15 μg. Competition curves were fitted by a nonlinear regression according to models assuming a single (dashed line) or two (solid line) binding sites. Graphs are representative of a single experiment out of three, each performed in triplicate (bars represent the S.D. of each triplicate determination). Spec. and Unsp. refer to specific and unspecific binding in the absence and presence of 2 mM dopamine set at 100% and 0%, respectively. (Sukalovic et al., 2015) . As shown in Table 1 (Fig. 3) , whereas no binding was detected in synaptosomes from dopamine D 3 receptor (D 3 −/−) KO mice.
Binding affinity of SB269,652 to multiple GPCRs
Interestingly, [ 3 H]SB269,652 displayed some specific binding also for the hM 4 muscarinic receptor. In particular, at a radioligand concentration of 10 nM of [ 3 H]SB269,652, a specific binding of 89.5 ± 13.7 fmol/mg was detected using CHO-hM 4 cell membranes, accounting for nearly 16% of the B max calculated with the specific muscarinic antagonist N-[ (Table 1) . No specific binding was detected on the other four classes of muscarinic receptor (data not shown). In view of this observation, we tested the affinity of cold SB269,652 for diverse classes of GPCR in comparison to hM 4 and other subtypes of muscarinic receptor. As shown in Table 4 , SB269,652 binds with high affinity to dopamine D 3 receptor and displayed lower affinity at dopamine D 2 receptors, yet it also revealed significant affinity for muscarinic hM 2 and hM 4 receptors, displaying IC 50 values of In order to address the effect of SB269,652 on dimeric dopamine D 3 receptor, we co-transfected dopamine D 3 and D 2 receptors in COS-7 cells. Significantly, these two receptors have been shown to interact with each other and to form heterodimers (Scarselli et al., 2001; Pou et al., 2012) . The activity of these two receptors can be easily distinguished in functional assays, as quinpirole inhibits forskolin mediated stimulation of ACVI only in COS-7 cells that co-express the dopamine D 2 receptor and the ACVI, whereas it has no effect in COS-7 cells co-transfected with the dopamine D 3 receptor and the ACVI (Fig. 4A) . In COS-7 cells co-expressing both dopamine D 2 and dopamine D 3 receptors and ACVI, the inhibitory effect of quinpirole on forskolin mediated activation of ACVI increased by four-fold in potency (Fig. 4A) .
The effect of SB269,652 on the ability of quinpirole to inhibit ACVI activity was tested on COS-7 cells transfected with either dopamine D 2 receptor alone, or co-transfected with dopamine D 2 and dopamine D 3 receptors. We observed that SB269,652 inhibited with very low potency and efficacy the action of quinpirole in dopamine D 2 receptor transfected cells (Fig. 4B) , whereas it was markedly more efficacious and potent at COS-7 cells co-expressing both dopamine D 2 and dopamine D 3 receptors (Fig. 4B) . Importantly, even though there was an increase in the ability of SB269,652 to counter the actions of quinpirole in cotransfected dopamine D 2 /D 3 receptor COS-7 cells, the inhibition was only partial and reached a plateau. The competitive antagonist SB277,011A, completely reversed the influence of quinpirole on forskolin-stimulated ACVI activity, both in dopamine D 2 receptor and in cotransfected dopamine D 2 /D 3 receptor cells (Fig. 4C) . SB277,011A was likewise more potent at cotransfected dopamine D 2 /D 3 receptor cells.
Discussion
In previous work we showed that SB269,652 displayed an atypical and allosteric-like pattern of interaction at dopamine D 3 receptor and, less potently, at dopamine D 2 receptor. The present study extends these observations in demonstrating that radiolabelled [ H]SB269,652 dissociation was triggered by dilution and the addition of excess of the ligands, dopamine and haloperidol, a two-ligand binding site model best described its behaviour. These observations are reminiscent of those acquired with other radioligands -including those that do not necessarily act via an allosteric mechanism. For example, the opioid antagonist, [ 3 H]naloxone benzoylhydrazone, binds to a single population of μ-opioid receptors in saturation binding experiments whereas kinetic studies reveal a biphasic dissociation (Brown and Pasternak, 1998 ]quinuclidinyl benzilate. In equilibrium binding experiments, these compounds bound to homogenous population of receptors yet, in kinetic experiments, the unlabelled ligands generated biphasic dissociation curves (Jakubík et al., 2000; Novi et al., 2003) . This notion is also underlined by May et al. (2011) in work with adenosine A 1 and A 3 receptors, which demonstrated that the dissociation rate constants of the fluorescent agonist ABA-X-BY630 markedly increased in the presence of orthosteric agonists or antagonists. Moreover, these authors proposed an innovative method for detecting cooperative interactions amongst two topographically distinct binding sites based on the dissociation kinetics of a tracer ligand in the absence vs presence of an additional, cold ligand. Accordingly, for the present studies with [ 3 H] SB269,652, an acceleration of its dissociation from dopamine D 3 receptor in the presence of the orthosteric antagonist, haloperidol, or the agonist, dopamine would be consistent with a negative type of cooperativity between the radioligand on one hand and the cold ligand on the other. Taken together, these observations underpin the importance of performing kinetic studies with competing cold ligands to unveil otherwise-hidden, multiple sites or affinity states for a radioligand. In line with the kinetic experiments discussed above, competition binding isotherms with haloperidol, the highly selective dopamine D 3 receptor antagonist S33084 (Cussac et al., 2000; Millan et al., 2000a Millan et al., , 2000b and dopamine were in each case consistent with two populations of binding sites. Taken together these competition binding and kinetic data suggest that [ The conserved aspartate residue in transmembrane region 3 of amine receptors plays a pivotal role in the docking of ligands to the orthosteric binding site (Vaidehi et al., 2014 explained either by a lack of ability of the mutant receptor to bind these radioligands or by the lack of its expression at the plasma membrane. This issue was addressed by complementing the dopamine D 3 D110A receptor mutant with truncated mutants of dopamine D 3 or dopamine D 2 receptors, this approach mirrors a previous work, in which, the ligand-binding and functional properties of truncated receptors were rescued by co-expressing complementary non-functional GPCR fragments (Scarselli et al., 2000 . In particular we found that the binding of both [ ,652, at least in part, to the orthosteric site of the dopamine D 3 receptor raises the issue of how this compound exerts its allosteric properties. One intriguing explanation may be found in the now broadly-accepted concept of GPCR homo-hetero-and higher order oligomerisation (Maggio et al., 2007; Scarselli et al., 2013 Scarselli et al., , 2016 Shivanandan et al., 2014) , which has been well-documented for dopamine D 3 receptor (Marsango et al., 2015 (Marsango et al., , 2017 Pou et al., 2012) . Dimerization can lead to crosstalk between protomers resulting in a cooperative pattern of ligand binding between them (Smith and Milligan, 2010) .
As mentioned above, dopamine D 3 receptor form homo- (Karpa et al., 2000; Marsango et al., 2015; Nimchinsky et al., 1997; Pou et al., 2012) and heteromers (Fiorentini et al., 2010; Maggio and Millan, 2010; Maggio et al., 2015; Scarselli et al., 2001; Pou et al., 2012) To test this idea, we co-transfected dopamine D 3 and dopamine D 2 receptors inasmuch they have been shown to form heteromers (Scarselli et al., 2001; Pou et al., 2012) , and can easily be distinguished in functional assays. In particular, when SB269,652 was tested at dopamine D 2 receptor alone, a modest reduction of quinpirole-induced inhibition of forskolin-stimulated ACVI activity was achieved at the higher concentrations of the drug. Conversely, when the dopamine D 3 receptor was co-transfected with dopamine D 2 receptor a much stronger inhibition and an increase in potency was obtained with SB269,652, even though the inhibition reached a plateau. As quinpirole did not have any effect on dopamine D 3 receptor alone, the data on co-transfected dopamine D 3 and dopamine D 2 receptors imply that SB269,652 binds to the dopamine D 3 receptor to inhibits the dopamine D 2 receptor via the dimer. Remarkably, a shift in potency was also observed with SB277,011A suggesting that mechanisms of cross inhibition can be relevant for other antagonists, potentially pure orthosteric ligands.
This potential mechanism of action is supported by the work of Lane et al. (2014) on dopamine D 2 receptor. They proposed that SB269,652 acts as a bitopic ligand composed of two bridged pharmacophores that simultaneously bind to the orthosteric and allosteric sites of the same receptor protomer. Importantly, they fragmented SB269,652 into two pharmacophores: 1), the 7-cyano-tetrahydroisoquinoline (7CN-THIQ) moiety that contains the tertiary amine, the part of the molecule that is important for the interaction with the conserved aspartic acid of the amine receptors in the orthosteric site and 2), the indole-2-carboxamide moiety that binds to an allosteric site of the dopamine D 2 receptor in a non-competitive manner. Furthermore, Shonberg et al. (2015) focusing on the three main chemical constituents of SB269,652, found that: a) the 7CN-THIQ binding to the orthosteric site of dopamine D 2 receptor is important for the orientation and binding of the indolcarboxamide to the allosteric site, and even subtle modifications of 7CN-THIQ affect the functional affinity and negative allosteric cooperativity of the molecule; b) the indole-2-carboxamide moiety of SB269,652 is important for its allosteric effect: SB269,652 analogues where indolic NH groups are substituted with others that are unable to generate hydrogen bonds lose the ability to allosterically interact with the receptor; c) linker length is critical for the allosteric effect of SB269,652 analogues. Lane et al. (2014) proposed that the binding of SB269,652 to one protomer of a dopamine D 2 receptor dimer changes its binding properties at the orthosteric site of the other promoter of the dimer. According to this concept, SB269,652 behaves as a competitive antagonist at receptor monomers yet as a negative allosteric modulator across receptor dimers.
This hypothesis -that seems to apply to dopamine D 3 receptor -is supported by the above-discussed data with the dopamine D 3 D110A receptor mutant, which lacks the aspartic acid in the orthosteric site crucial for binding of the tertiary amine in the 7CN-THIQ moiety of [ 3 H]SB269,652. Moreover, in a previous study using chimeric dopamine D 2 /D 3 receptor (Silvano et al., 2010) , we showed that the extracellular loop II of the dopamine D 3 receptor plays a pivotal role in binding SB269,652, which further supports the concept that this loop could bind the indole-2-carboxamide fragment of this compound.
While this hypothesis is compelling, it does not necessarily account for all the results generated with SB269,652 at dopamine D 3 receptor. Thus, we previously demonstrated that SB269,652 does not behave as a classic negative allosteric modulator: at high concentrations, in fact, it reduces radioligand dissociation rate constants at dopamine D 2 and dopamine D 3 receptors (Silvano et al., 2010) . Conversely, as shown herein, dopamine and haloperidol accelerated the dissociation of a fraction of [ 3 H]SB269,652 from CHO-D 3 cell membranes. The most parsimonious explanation to reconcile these apparently contrasting results would be that SB269,652 binds in two ways: when the orthosteric site is occupied by a ligand, SB269,652 would still be able to physically interact with the monomer through the receptor allosteric site and it would physically occlude the orthosteric site so that competitive antagonists would be unable to readily leave (or enter) the orthosteric site (Fig. 5A) . The lack of binding of [ 3 H]SB269,652 to the dopamine D 3 D110A receptor mutant, in which the bitopic interaction of the radioligand is prevented, could be explained by the much lower affinity of the radioligand bound to the sole allosteric site. On the other hand, when the receptor is unoccupied, SB269,652 would bind as a bitopic ligand to both orthosteric and allosteric binding sites of a single dopamine D 3 receptor protomer, and orthosteric ligands would increase its dissociation by binding to the sibling protomer in the corresponding dimer (Fig. 5B) . The allosteric properties of SB269,652 would then strictly depend on the ligand bound to the sibling protomer. In this context, the recognition of a single population of binding sites in saturation binding experiments and in studies of dissociation kinetic started by dilution, suggest that when SB269,652 binds to one protomer in a dimer, it does not alter the binding of molecules of SB269,652 to the other protomer. A similar mechanism of binding and allostery has been described for the antagonist methoctramine at muscarinic M 2 receptors (Jakubík et al., 2014 
